AXGN Axogen, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 805928 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.3%
TTM net income YoY-1,422.3%
TTM EPS YoY-1,160.0%
Revenue 3-yr CAGR20.6%
Net income 3-yr CAGR—
Margins
Gross margin74.2%
Operating margin-5.2%
Net margin-12.0%
FCF margin8.3%
EBITDA margin-2.8%
Returns
ROE-10.3%
ROA-8.3%
ROIC (approx.)-7.1%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio12.02x
Interest coverage-5.72x
Cash quality & payout
Operating cash flow / net income-0.89x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $75.83M | $69.73M | $61.46M | $59.90M | $60.08M | $56.66M | $48.56M | $49.41M |
| Cost of revenue | $19.10M | $19.06M | $15.27M | $15.49M | $14.09M | $14.64M | $13.63M | $11.83M |
| Gross profit | $56.73M | $50.67M | $46.19M | $44.41M | $45.99M | $42.02M | $34.93M | $37.58M |
| R&D expense | $8.95M | $8.59M | $7.52M | $12.38M | $7.57M | $6.85M | $6.09M | $6.70M |
| SG&A expense | $16.46M | $13.41M | $12.87M | $14.59M | $10.84M | $9.69M | $9.46M | $8.83M |
| Operating income | $955,000 | -$2.16M | -$2.83M | -$9.77M | $1.91M | $1.67M | -$1.66M | $2.02M |
| Interest expense | $1,000 | $1,000 | $694,000 | $1.72M | $1.76M | $1.98M | $2.25M | $1.80M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $2.33M | -$1.52M | -$19.58M | -$13.16M | $708,000 | $579,000 | -$3.83M | $450,000 |
| EBITDA | $2.53M | -$549,000 | -$1.23M | -$8.14M | $3.55M | $3.33M | $67,000 | $3.65M |
| EPS (basic) | 0.04 | -0.03 | -0.38 | — | 0.02 | 0.01 | -0.08 | — |
| EPS (diluted) | 0.04 | -0.03 | -0.38 | — | 0.01 | 0.01 | -0.08 | — |
| Weighted avg. shares (diluted) | 61.53M | 53.34M | 51.59M | — | 49.09M | 47.98M | 45.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $328.89M | $94.57M | $82.65M | $35.55M | $27.90M | $26.04M | $24.10M | $33.55M |
| Short-term investments | $19.18M | $16.84M | $18.95M | $5.98M | $11.89M | $9.89M | $3.97M | $5.93M |
| Receivables | $34.01M | $34.13M | $28.31M | $26.17M | $30.77M | $28.03M | $26.30M | $24.11M |
| Inventory | $49.06M | $47.31M | $46.07M | $42.37M | $40.58M | $36.77M | $35.50M | $33.18M |
| Current assets | $438.09M | $200.38M | $184.71M | $120.42M | $114.46M | $103.42M | $93.07M | $99.22M |
| PP&E, net | $81.95M | $82.34M | $83.04M | $81.78M | $82.37M | $82.39M | $83.31M | $84.67M |
| Intangibles | $7.91M | $7.57M | $7.27M | $6.75M | $6.43M | $6.12M | $5.88M | $5.58M |
| Total assets | $550.34M | $304.86M | $289.49M | $221.69M | $216.40M | $205.45M | $196.16M | $203.73M |
| Current liabilities | $36.46M | $30.37M | $26.01M | $23.56M | $28.01M | $24.98M | $21.75M | $30.61M |
| Long-term debt | $0 | $0 | $0 | $48.39M | $48.16M | $47.94M | $47.72M | $47.50M |
| Total debt | $0 | $0 | $0 | $48.39M | $48.16M | $47.94M | $47.72M | $47.50M |
| Total liabilities | $54.24M | $48.61M | $44.68M | $92.84M | $95.59M | $93.18M | $90.80M | $99.82M |
| Shareholders' equity | $496.10M | $256.26M | $244.81M | $128.85M | $120.81M | $112.28M | $105.36M | $103.91M |
| Net debt | -$328.89M | -$94.57M | -$82.65M | $12.84M | $20.26M | $21.90M | $23.62M | $13.94M |
| Shares outstanding | 59.72M | 53.66M | 53.15M | 47.20M | 46.12M | 45.77M | 45.51M | 44.15M |
| Cash flow statement | ||||||||
| Operating cash flow | $16.54M | $7.22M | $1.56M | $3.04M | $3.22M | $7.73M | -$13.18M | $8.73M |
| Capital expenditure | $1.39M | $893,000 | $2.79M | $1.25M | $1.52M | $722,000 | $256,000 | $670,000 |
| Free cash flow | $15.14M | $6.33M | -$1.22M | $1.79M | $1.70M | $7.01M | -$13.44M | $8.06M |
| Investing cash flow | -$10.93M | $500,000 | -$15.96M | $4.04M | -$3.75M | -$6.95M | $1.34M | -$813,000 |
| Financing cash flow | $228.71M | $4.20M | $59.51M | $4.57M | $2.39M | $1.16M | $2.38M | $970,000 |
| Depreciation & amortization | $1.58M | $1.61M | $1.60M | $1.63M | $1.64M | $1.66M | $1.73M | $1.64M |
| Stock-based compensation | $8.79M | $8.77M | $6.84M | $16.61M | $5.42M | $5.17M | $2.91M | $3.08M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.